High prevalence of macrolide resistant *Treponema pallidum* strains in a London centre

Craig Tipple, Myra O McClure, Graham P Taylor

Jefferiss Trust Laboratories,
Wright-Fleming Institute,
Imperial College London,
London, UK

Correspondence to

Dr Craig Tipple, Clinical
Research Fellow, Jefferiss Trust
Laboratories, Wright-Fleming
Institute, Imperial College
London, Norfolk Place, London
W2 1PG, UK;
c.tipple@imperial.ac.uk

Accepted 19 July 2011

ABSTRACT

Objectives Macrolide resistant *Treponema pallidum* strains, caused by mutations in the 23S ribosomal RNA (23S rRNA) gene, are widespread and increasingly prevalent. The authors aimed to establish the strain types of *T. pallidum* isolated from patients in a London sexual health centre and to determine the frequency of macrolide resistance.

Methods *T. pallidum* DNA from blood and ulcer samples were subjected to strain typing and mutation analysis using previously described methods.

Results 18 samples were tested and a 23S rRNA point mutation conferring macrolide resistance was found in 66.6%. All resistant strains were collected from men who have sex with men and both the A2058G and the A2059G mutations were found. Two strain types were identified (14d/g and 14d/f); the predominant strain type was 14d/g and an association was noted between *tp0548* type g and macrolide resistance.

Conclusions High levels of *T. pallidum* macrolide resistance are present in London, UK, and this has clear implications for national treatment guidelines.

INTRODUCTION

British guidelines for the management of syphilis include macrolide antibiotics as alternative treatments for incubating and early disease.¹ This advice comes with the caveat that intrinsic macrolide resistance is present in some strains of *Treponema pallidum*, although the UK prevalence is unknown.

Following trials showing comparable efficacy to benzathine penicillin, single-dose azithromycin was adopted for the treatment of incubating and early disease.^{2–3} This was followed by reports of treatment failures, mostly among men who have sex with men (MSM), attributed to a single point mutation in the *T. pallidum* 23S ribosomal RNA (23S rRNA) gene, a mutation that is now geographically widespread and increasingly prevalent.^{3–4}

In addition to the detection of resistance mutations, molecular analysis of *T. pallidum* allows the identification of different strains and while there are common types, considerable diversity within epidemics has been demonstrated.⁵

In this study, we present genotypic evidence of macrolide resistance and strain typing data from London, UK.

METHODS

Study participants and specimens

Samples were collected from patients attending St Mary's Hospital, London (July 2006–January 2008) in a cross-sectional study of *T. pallidum* infection following ethical approval from the Hounslow and Hillingdon Research Ethics Committee.⁶

23S rRNA mutation detection

As previously described, a section from each copy of the *T. pallidum* 23S rRNA gene (Genbank ref. AF200367) was PCR-amplified from extracted DNA.⁴ Separate aliquots of each amplicon were digested using the restriction endonucleases *Mbo*-II and *Bsa*-I and the resultant digestion pattern was analysed.^{4–7} For confirmation, the gene sequence of a third (undigested) aliquot was determined using the Applied Biosystems dRhodamine kit and 3100 capillary sequencer.

Plasmids containing DNA from Street 14 strain (an A2058G mutant obtained from a patient who failed macrolide therapy) or UW228B (A2059G mutant) constituted positive controls for both the initial PCR and the enzymatic digestion.

Strain typing

Identification of strains was based on the *arp*, *tpr* and *tp0548* genes, as described.^{4–7} To summarise: following PCR amplification, the size of the *arp* amplicons, determined by agarose gel electrophoresis, is compared with Nichols strain *T. pallidum*, which is known to contain 14 repeats of a 60 base pair sequence. The number of repeats forms the first part of the type (14, 15, etc). The second part requires *Mse*-I restriction digestion of the *tpr* amplicon for comparison of the resulting digestion pattern with standard profiles. Each pattern is assigned a letter (a, b, etc). Finally, the sequence of the *tp0548* gene amplicon is compared with one of a number of previously established sequences (a, b, etc).

RESULTS

T. pallidum from 18 patients was available for analysis. All subjects were male, median age 37 years (range 24–54) and 61.1% were HIV-1 positive (table 1). Where sexual orientation was stated, 94.1% were MSM.

23S rRNA mutation analysis

23S rRNA mutations were identified in 12/18 (66.6%) samples of which 11 had the A2058G substitution (table 1). All 23S rRNA mutations were present in both copies of the gene.

Strain subtype analysis

Twelve samples had sufficient DNA remaining for strain-type analysis, resulting in the identification of five full and seven partial strain types (table 1). Where analysis of *arp* and *tpr* genes succeeded, only the 14d type was detected. Sequence analysis of the *tp0548* gene classified these as 14d/g (four isolates) and 14d/f (one isolate) strains.

Table 1 Demographic, typing and mutation data

Case number	Age (years)	Sexual orientation	HIV-1 status	Stage of disease	Sample type	Number of arp repeats	tpg gene mse-1 digest pattern	tp0548 sequence	Full strain type	23S rRNA type
1	31	Homosexual	Negative	Secondary	Ulcer	—	d	g	—	A2058G
2	34	Homosexual	Negative	Primary	Ulcer	14	d	g	14d/g	A2058G
3	50	Homosexual	Negative	Primary	Ulcer	14	d	g	14d/g	A2058G
4	24	—	Positive	Primary	Ulcer	—	—	—	—	Wild-type
5	43	Homosexual	Positive	Secondary	Blood	—	—	—	—	A2058G
6	38	Homosexual	Positive	Primary	Ulcer	14	d	g	14d/g	A2058G
7	28	Homosexual	Negative	Primary	Ulcer	—	—	g	—	A2058G
8	42	Homosexual	Positive	Secondary	Ulcer	—	—	f	—	Wild-type
9	41	Homosexual	Positive	Secondary	Blood	—	—	—	—	A2058G
10	33	Homosexual	Positive	Primary	Ulcer	14	d	f	14d/f	A2058G
11	38	Homosexual	Positive	Secondary	Blood	—	—	—	—	Wild-type
12	30	Homosexual	Positive	Secondary	Blood	—	—	—	—	A2058G
13	54	Heterosexual	Positive	Primary	Ulcer	14	—	f	—	Wild-type
14	30	Homosexual	Negative	Primary	Ulcer	—	—	g	—	A2058G
15	45	Homosexual	Positive	Secondary	Blood	—	—	—	—	A2059G
16	36	Homosexual	Positive	Primary	Ulcer	14	d	g	14d/g	A2058G
17	47	Homosexual	Negative	Primary	Ulcer	14	—	f	—	Wild-type
18	31	Homosexual	Negative	Primary	Ulcer	—	—	f	—	Wild-type

23S rRNA, 23S ribosomal RNA.

In total, 7 of the 12 *tp0548* gene sequences were 'g' and the remaining 5 were 'f' of which 4 had wild-type 23S rRNA sequences and 1 was an A2058G mutant.

No association was identified between HIV-1 status and either full *T pallidum* subtype or type according to *tp0548* sequence alone.

DISCUSSION

White MSM account for around three-quarters of syphilis cases in the UK and HIV-1 co-infection (34%) is common.⁸ Patients with early syphilis participating in this study (2006–2008) were also predominantly white MSM (94.1%); 61.1% were HIV-1 positive and two-thirds of the *T pallidum* isolates had genotypic evidence of resistance to macrolide antibiotics. These findings, the first such data from the UK, have implications for syphilis treatment guidelines.¹

In San Francisco, the prevalence of resistant strains increased from 4% in 2000–2002 to 56% in 2004. This coincided with guidelines that included the use of azithromycin as an alternative for the treatment of incubating and subsequently early syphilis.³ While azithromycin has never been the preferred therapy for the management of syphilis in the UK, it has been increasingly prescribed for the treatment of non-specific urethritis and chlamydia. Samples prior to 2006 were not available to assess changes in the prevalence of resistant strains.

Key messages

- In two thirds of syphilis cases seen at our London centre, the causative *Treponema pallidum* has a mutation conferring high-level macrolide resistance.
- The recent increase in *Treponema pallidum* infections is driven by more than one strain.
- Macrolide antibiotics should be avoided for the treatment of incubating or early syphilis, especially for gay men in London.

The suggestion that a single resistant strain may enter a population and become endemic is supported by evidence that the 23S rRNA mutation in the Street 14 strain is stable, when passaged in untreated rabbits.^{5,9} In this scenario, a mutant strain would have been imported into the London MSM population where it became the predominant circulating strain. If all the 23S rRNA mutants were a single clone, we would expect only one subtype. However, subtype analysis from this and other studies presents a more complex picture. Four of the full subtypes identified were 14d/g and the fifth was 14d/f. The higher level of success achieved by typing *T pallidum* from ulcer samples than from blood probably reflects the relative bacterial loads.⁶ While the number of full subtypes identified in this study was limited, other molecular epidemiology studies of syphilis in Scotland and Canada have identified several subtypes within these populations.^{5,10} It seems likely, therefore, that neither these epidemics nor the London epidemic represent the spread of a single clone, and a significant role for antibiotic selection pressure is suggested. This is supported by epidemiological evidence that macrolide exposure in the 3 months prior to syphilis diagnosis is associated with a 30% increase in resistance.⁹

In summary, we have shown that genotypic macrolide resistance in *T pallidum* is common in MSM in London and, therefore, we recommend caution in the use of macrolides for the treatment of syphilis, particularly in this MSM population. Although limited, our typing data suggest that the syphilis epidemic in London is not a single clone of resistant *T pallidum*, raising the possibility that resistance mutations are developing de novo.

Acknowledgements The authors thank Professor Sheila Lukehart, University of Washington, Seattle, for donation of samples and advice.

Funding This study was supported by the Mason Medical Foundation and the Imperial College Healthcare Biomedical Research Centre.

Competing interests None.

Ethics approval This study was conducted with the approval of Hounslow and Hillingdon REC.

Contributors CT: undertook the experimental work described, analysed the data, wrote the first draft of the manuscript and approved the final published version. MOM: study

concept and design, critical revision of the manuscript for scientific concept and approved the final published version. GPT: Study concept and design, critical revision of the manuscript for scientific concept and approved the final published version.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

1. **Kingston M**, French P, Goh B, *et al.* UK National Guidelines on the Management of Syphilis 2008. *Int J STD AIDS* 2008;**19**:729–40.
2. **Riedner G**, Rusizoka M, Todd J, *et al.* Single-dose azithromycin versus penicillin G benzathine for the treatment of early syphilis. *N Engl J Med* 2005;**353**:1236–44.
3. **Katz KA**, Klausner JD. Azithromycin resistance in *Treponema pallidum*. *Curr Opin Infect Dis* 2008;**21**:83–91.
4. **Lukehart S**, Godornes C, Molini B, *et al.* Macrolide resistance in *Treponema pallidum* in the United States and Ireland. *N Engl J Med* 2004;**351**:154–8.
5. **Cole M**, Chisholm S, Palmer H, *et al.* Molecular epidemiology of syphilis in Scotland. *Sex Transm Infect* 2009;**85**:447–51.
6. **Tippel C**, Hanna M, Hill S, *et al.* Getting the measure of syphilis: qPCR to better understand early infection. *Sex Transm Infect* 2011;**87**:479–85.
7. **Matejková P**, Flasarová M, Zákoucká H, *et al.* Macrolide treatment failure in a case of secondary syphilis: a novel A2059G mutation in the 23S rRNA gene of *Treponema pallidum* subsp. *pallidum*. *J Med Microbiol* 2009;**58**:832–6.
8. **Health Protection Agency UK**. *Syphilis and Lymphogranuloma Venereum: Resurgent Sexually Transmitted Infections in the UK*, 2009. http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1245581513523 (accessed 23 Jun 2011).
9. **Marra CM**, Colina AP, Godornes C, *et al.* Antibiotic selection may contribute to increases in macrolide-resistant *Treponema pallidum*. *J Infect Dis* 2006;**194**:1771–3.
10. **Martin IE**, Tsang RS, Sutherland K, *et al.* Molecular typing of *Treponema pallidum* strains in western Canada: predominance of 14d subtypes. *Sex Transm Dis* 2010;**37**:544–8.

Letter

Assessing the understanding and prior uptake of human papillomavirus vaccination among eligible females attending genitourinary medicine clinics in UK

In 2008, the UK human papillomavirus vaccination programme was introduced to vaccinate all 12–13-year-old girls, with a 2-year catch up for those aged up to 18 years. Delivery has been principally through schools and general practitioners, although concern remains that all groups are not being reached and the full three doses may not be received by all. Many young sexually active females attend genitourinary medicine (GUM) clinics; therefore, this may be a potential location for vaccine delivery.

In order to assess knowledge and prior vaccine uptake, a survey was conducted in five UK GUM clinics. A questionnaire and information leaflet was approved by the Northern Ireland Research Committee and distributed from August to December 2009. Eligible females were those born between the years 1990 and 1996 inclusive (ie, aged 12–18 years when the programme was introduced). Questionnaires were distributed by the reception staff to consecutive patients and completed unsupervised.

Five-hundred and fifty-eight questionnaires were returned; however, 65 (12%) were excluded due to incomplete data. Of the remaining 493, 25 (5%) were aged under 15 years, 241 (49%) 15–16 years and 227

(46%) 17–18 years old. The majority (85%) of respondents had heard of the human papillomavirus vaccine; however, only 26% had received one or more doses. Only 40% of those who received the vaccine knew which vaccine was given. Ninety per cent stated they would accept the vaccine if offered at a GUM clinic and, given the choice, 13% would prefer Cervarix, 38% Gardasil and 49% remained unsure.

It appears health promotion strategies have been effective given that the majority of respondents were aware of the programme; however, the uncertainty regarding which vaccine was received suggests information disseminated about the two commercially available vaccines has not been grasped. After reading the information provided, those who made a choice showed a clear preference for Gardasil.

Vaccine uptake among those surveyed is disappointing and falls short of the Department of Health figures.¹ Given the large number of young sexually active females attending GUM clinics, it would appear an ideal location for participation and improve vaccine uptake.

Recent sexually transmitted infection figures from GUM clinics in UK show a continuing increasing trend of infections.² There is an opportunity for a major contribution to disease prevention by considering quadrivalent vaccine. Evidence from Australia of the reducing prevalence of genital warts further strengthens this argument.³ The next round of UK contracting is imminent and we would urge switching to quadrivalent vaccine to maximise

programme benefits and relieve the ever-growing pressure on GUM services.

E J McCarty,¹ C O'Mahony,² S Bates,³ P Fox,⁴ R D Maw¹

¹Department of Genitourinary Medicine, Royal Victoria Hospital, Belfast Health and Social Care Trust, UK;

²Department of Genitourinary Medicine, Countess of Chester Foundation Trust Hospital, Chester, UK;

³Department of Genitourinary Medicine, Royal Hallisham Hospital, Sheffield Teaching Hospitals, UK; ⁴Department of Genitourinary Medicine, Ealing Hospital, Southall, UK

Correspondence to E J McCarty, Department of Genitourinary Medicine, Royal Victoria Hospital, Grosvenor Road, Belfast BT12 6AB, UK; ej_mccarty@hotmail.com

Competing interests None.

Ethics approval Northern Ireland Ethics Committee.

Provenance and peer review Not commissioned; internally peer reviewed.

Accepted 17 July 2011

Sex Transm Infect 2011;**87**:488.
doi:10.1136/sextrans-2011-050142

REFERENCES

1. **Health Protection Agency**. *Annual HPV Vaccine Uptake in England, 2008–2009*. <http://www.dh.gov.uk>.
2. **Health Protection Agency**. *Trends in STI Diagnosis UK and England, 2008–2009*. <http://www.hpa.org.uk> (accessed 2 Apr 2011).
3. **Fairley CK**, Hocking JS, Gurrin LC, *et al.* Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. *Sex Transm Infect* 2009;**85**:499–502.